ARA 290 Nasal Spray 20 mg – 10 ml

ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide engineered from the three-dimensional structure of helix B of erythropoietin (EPO). Unlike full-length recombinant EPO, ARA-290 is non-erythropoietic — it does not bind the classical EPOR homodimer responsible for red blood cell production, and therefore avoids the hematological risks associated with erythropoietin therapy. Instead, the peptide selectively activates the innate repair receptor (IRR), a tissue-protective heteromeric complex composed of one EPOR subunit and the β-common receptor (βCR / CD131). The IRR is minimally expressed under baseline conditions but becomes locally upregulated in response to cellular stress, injury, or inflammation across multiple cell types including neurons, endothelial cells, macrophages, and glial cells. ARA-290 has been studied in preclinical and clinical research for over a decade as a tissue-protective, anti-inflammatory, and neuropathic-pain research compound, holding FDA Orphan Drug designation for sarcoidosis-associated neuropathy.

Product Highlights

• Each vial contains 10 mL solution (~100 sprays)

• Each spray delivers 0.1 mL = 200 mcg ARA-290

• Total ARA-290 Content: 20 mg per vial

• Specialized pharmaceutical-grade nasal solution — designed for comfort and ease on the nose

• Unlike many other nasal sprays, this formula avoids irritation and dryness

• Packaged in Class A, lead-free pharmaceutical glass bottles

• Tamper/Child-Proof Cap + Orifice Reducer for integrity, sterility, and ease of use

Description

ARA-290 is explored for selective innate repair receptor (IRR) activation and non-erythropoietic tissue protection, with research interest in neuroinflammation modulation, small nerve fiber regeneration, anti-apoptotic signaling, wound healing, and immunomodulatory pathways without hematopoietic effects.

Benefits

• Innate repair receptor activation — studied as a selective IRR (EPOR/CD131) agonist without classical EPOR homodimer binding

• Non-erythropoietic — investigated for retaining EPO’s tissue-protective effects without stimulating red blood cell production

• Neuroinflammation modulation — explored for suppression of TNF-α, IL-6, IL-12, and NF-κB pathway signaling

• Small nerve fiber research — examined for corneal nerve fiber density restoration in sarcoidosis and diabetic neuropathy models

• Anti-apoptotic signaling — linked to cellular survival and tissue-protective gene expression upregulation

• Immunomodulatory action — researched for macrophage activation balance and microglial response in CNS injury models

Localized Effects with Nasal Spray

• Rapid absorption through the nasal mucosa

• Direct olfactory and trigeminal nerve pathway access to the central nervous system

• Bypasses first-pass hepatic metabolism that limits oral peptide bioavailability

• Particularly relevant for CNS neuroinflammation research given direct nose-to-brain pathway

• Convenient delivery route for IRR pharmacology and tissue-protection studies

• Formulated with a specialized isotonic nasal vehicle to minimize irritation and dryness

What Researchers Use It For

• Innate repair receptor (IRR) pharmacology and EPOR/CD131 signal transduction studies

• Inflammatory cytokine profiling (TNF-α, IL-6, IL-12) and NF-κB pathway activation

• Small nerve fiber regeneration in diabetic and sarcoidosis-associated neuropathy models

• Neuroinflammation and microglial activation endpoints in CNS injury models

• Wound healing research in diabetic and impaired-repair preclinical models

• Macrophage polarization and immune cell recruitment investigations

Identity & Specs

• Compound: ARA-290

• Synonyms: Cibinetide; PH-BSP; helix B surface peptide

• Class: Non-erythropoietic EPO-derived peptide; innate repair receptor (IRR) agonist (11 amino acids)

• Sequence: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH (ZEQLERALNSS)

• Formula / M.W.: C₅₁H₈₄N₁₆O₂₁, ~1257.31 g/mol

• CAS: 1208243-50-8

• PubChem CID: 91810664

• Form: Sterile nasal spray solution

• Net per vial: 10 mL (~100 sprays)

• Total Content: 20 mg ARA-290 per vial

• Concentration: 2.0 mg/mL (200 mcg per 0.1 mL spray)

• Purity: ≥99% (HPLC)

• Identity: MS-verified (per COA)

• Storage: Refrigerate 2–8 °C, protect from light

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.